PubMed Health⌕ Search

Biomedical subjects

V M Dil'man

Publications and source records attributed to V M Dil'man.

At least 19 recordsLinked to original sources
PubMed1995

[The relation of a number of hormonal indices to risk factors for IHD and its prevalence based on the data from a large population study].

Relevance of IHD risk factors and hormone concentrations (insulin, estradiol, testosterone, prolactin, LH, FSH, TTH and hydrocortisone) to IHD incidence was studied in 1200 men. Multivariate statistical analysis demonstrated that only a small number of hormonal indices are associated with main lipid and nonlipid risk factors. The relationships exist between systolic arterial pressure (SAP) and hydrocortisone, between TTH and total cholesterol, SAP and age, estradiol, testosterone and age. Significant independent associations were found between IHD prevalence and age (R = 0.140, 3 = 0.000), SAP (R = 0.130, P.0.001), HDLP cholesterol (R = -0.082, P = 0.007), height (R = -0.078, P = 0.010), insulin (R = 0.067, P = 0.035), standard deviation of estradiol from median value (R = 0.083, P = 0.017). The findings confirm a great role of high SAP in the development of IHD, a significant and independent association of high insulin levels with IHD prevalence, the presence of nonlinear relation of estradiol concentration to IHD occurrence in males.

Adult↗
PubMed1991

[Detection of antibodies to adipose tissue cell membranes in human blood].

In serum of some healthy women and patients with fibroadenomatosis of the mammary gland antibodies to the cell membranes of adipocytes were detected. Interconnections between these antibodies and corresponding antigens in blood, on the one hand, and hormonal-metabolic status of probands, on the other hand, were observed. Possible autoimmune origin of phenomenon detected and its relation to the normal and pathological processes in adipose tissue are discussed.

Adenofibroma↗
PubMed1990

[Aromatase activity in lymphocytes of cancer patients and healthy subjects].

Conversion of androgens (aromatization) to estrogens in lymphocytes of cancer patients and healthy subjects in vitro was discovered. Aromatase activity in lymphocytes was comparable to that of fat and breast tumor tissues. It was completely suppressed in one out of two breast cancer patients receiving orimeten (aminoglutethimide). The activity in large bowel cancer was lower than in adenoma patients; however, the two groups were not balanced for age.

Adenofibroma↗
PubMed1990

[Hyperprolactinemia as a marker of the progression of cervical cancer].

Elevated blood prolactin level was identified in 80% of untreated patients with advanced (stage II-IV) cervical cancer whereas it was normal at the earlier (preinvasive) stage. Patients with stage I-A, II tumors revealed either increased or normal blood prolactin level. Patients with advanced cancer who had undergone irradiation and surgery, either alone or in combination, showed hyperprolactinemia as often as 94% of the time. Studies on pathogenesis of hyperprolactinemia and its role in tumor progression are currently conducted by the authors.

Adult↗
PubMed1989

[Aging and cancer: the foundation of strategies of ontogenetic prophylaxis].

According to the recent conceptions the ecological harmful factors are the main causes producing the cancer appearance, especially of the age-dependent elevation of its incidence. It is known that the key element of cancer prevention is a decrease or removal of exogenous carcinogens. Such a way can lead to the decrease of the cancer incidence in the young and middle aged persons and to the increase of the cancer frequency in the old age, i.e. to the increase of the cancer incidence in population on the whole, because metabolic conditions promoting the cancer appearance in an organism regularly appear in the process of aging. These conditions arise as a by-product of the organism developmental programme. New approaches to the cancer prevention are considered as based on principles of the ontogenetic prevention.

Aged↗
PubMed1989

[Body weight, blood lipids, blood cortisol and prognosis of patients with cancer of the large intestine and breast].

Survival was evaluated in 121 patients with breast cancer and 114 with colorectal tumors versus overweight, body surface, preoperative blood-cholesterol level, cholesterol fraction profile and blood-triglyceride and -11-hydroxycorticosteroid levels. Survival was assessed by actuarial method. In breast cancer patients, prognosis inversely correlated with overweight and preoperative blood-cholesterol level whereas in colorectal cancer--with preoperative blood-triglyceride level, and--in males--with those of 11-hydroxycorticosteroids. The prognostic significance of cancrophilia factors in cancer as well as differences in said significance for colorectal and breast tumors are discussed.

11-Hydroxycorticosteroids↗
PubMed1988

[Somatomedin activity in patients with malignant neoplasms].

The effect of tumor on somatomedin level in blood was investigated. This index, which is generally high in patients with primary tumors of the breast, cervix uteri, colon rectum and prostate, was found to decrease in step with tumor progression (stages II-IV). In well--differentiated adenocarcinoma of the endometrium and large bowel, it was higher than in moderately- and poorly-differentiated forms. In breast cancer patients, a relatively high blood--somatomedin level was mostly observed in solid forms, this being matched by relatively high somatomedin levels in tumor tissue. The tissue of 60% of large bowel tumors was shown to produce an inhibitor of somatomedin activity. It is suggested that there is a relationship between blood-somatomedin level in cancer patients and tumor mediated by somatomedin-like and -inhibiting factors produced by it.

Adenocarcinoma↗
PubMed1988

[Somatomedin activity of the blood: hormonal metabolic and immunological shifts in cancer patients].

Blood somatomedin activity observed in patients with cancer of the corpus uteri, breast, colon and rectum, pancreas, ovary and lung proved to exceed those in control by 140-300%. The said parameter was found to depend upon endocrine-metabolic changes, relatively higher levels being registered in overweight patients and those with hypertriglyceridemia. Changes of varying degree in somatomedin activity and growth hormone levels produced by insulin and glucose in patients with breast and uterine cancer pointed to hormonal dependence of the parameter. Also, the effect is a circumstantial evidence for negative feedback between growth hormone and somatomedin production. In patients with cancer of the breast, uterus and lung, a significant correlation was established between somatomedin activity, on the one hand, and monocyte. B-lymphocyte and T-active lymphocyte levels, on the other, matched by an inverse one with T-lymphocyte level and blastogenic reaction of lymphocytes.

Carbohydrates↗
PubMed1988

[Capacity of rhabdomyosarcoma cells to produce substances with somatomedin and mitogenic activity].

The rats aged 1, 3, 12 and 15 months were intravenously injected with 10,000 of the rhabdomyosarcoma cells. 3 weeks following the injection multiple tumour clones were observed in the lungs of experimental animals, the rats aged 1 and 15 months showing a significantly greater tumour yield than those aged 3 and 12 months. The level of the mitogenic and somatomedin activity increased both in the blood serum and in the lung tissue, the activity varying with the number of tumour clones. Rhabdomyosarcoma cells, probably, synthesize and release growth factors into the blood.

Animals↗
PubMed1987

[Immunocorrective therapy in esophageal cancer].

Additional non-specific therapy including levamisole and other drugs was tested in 20 patients with esophageal cancer. Complex (immuno- and chemoradiation) treatment brought immune response, lipid metabolism and cortisol level to normal, which in most cases, was in correlation with the clinical effect of therapy.

Adjuvants, Immunologic↗
PubMed1986

[Characteristics of dyslipidemia in cancer patients].

Blood concentrations of total cholesterol, cholesterol of very high density lipoproteins (alpha-cholesterol), triglycerides, beta-lipoproteins and 11-hydroxycorticosteroids were studied in 560 patients with rectal, colon, lung, ovarian, breast and endometrial cancer as well as in 238 controls. Patients with breast and rectal cancer were examined before and repeatedly after operation (every 6-12 months within 4-5 years). The blood concentration of total cholesterol was found to be elevated in breast cancer patients and controls with fibroadenomatosis and decreased in females with ovarian cancer and males with lung cancer. The level of blood alpha-cholesterol was decreased in males with all tumor localizations under study and in females with ovarian and rectal cancer. The concentration of triglycerides was increased in women patients only. Three possible causes of dyslipidemia in cancer patients are discussed: its development before tumor manifestation, the effect of tumor on the metabolic status of the host and the role of emotional stress in the increase of triglycerides level in the blood of primary cancer patients.

11-Hydroxycorticosteroids↗
PubMed1985

[Cyclic adenosine monophosphate content in the lymphocytes of cancer patients].

Examinations have been carried out on 83 cancer patients (aged 34-72), 24 patients with atherosclerosis (aged 38-68) and 34 healthy persons (aged 20-69). The cAMP concentration decrease with age in lymphocytes of healthy persons is confirmed. This index in patients with lung carcinoma, breast carcinoma in remission and in patients with atherosclerosis was identical with that of healthy persons, but in patients with breast and corpus uteri carcinomas without metastases it was higher than in healthy persons of the similar age. The amount of cAMP in lymphocytes is compared with the magnitude of the blast transformation and with the amount of cholesterol in blood and lymphocytes in examined persons. The cAMP level in lymphocytes is observed to increase in the process of hyperlipidemia disappearance in cancer patients and in those with atherosclerosis.

Adult↗